GMAB

GENMAB A/S

Healthcare · Biotechnology

$189.45 sample

+1.21 (+0.64%) 1D

Market cap

$1.17T

Price as of

2026-10-05

Latest filing

8-K · 2026-09-23

Alerts

8

Price$189.45 +18.32% 3M daily closessample

189.45156.99

2026-07-082026-07-302026-08-212026-09-112026-10-05

purchase / approvalsale / rejectionfiling / neutral

Latest events

Filings, trades, FDA; newest first

Sep 30INSInsider sell: Chief Executive Officer
Sep 23SECForm 144 filed
Sep 17INSInsider sell: Chief Financial Officer
Sep 09SECDEF 14A filed
Sep 03INSInsider buy: Director
Aug 31SEC8-K filed: material event
Aug 26INSInsider sell: General Counsel
Aug 19INSInsider sell: 10% owner

Sign up to see the real GMAB record →

Company facts

SEC EDGAR registration

Name: GENMAB A/S
Sector: Healthcare
Industry: Biotechnology
Smart-money score: -16sample, -100 to +100
Reporting currency: USD

Who is positioning in GMAB

sample

Insiders: 18 insider transactions over 90 days, net selling, $307.2M
Congress: 3 members traded over 90 days
Institutions · 13F: 38 funds hold $17.7B
Activists · 13D/G: No 13D/13G activist filings on record

How are the fundamentals trending?

sample, by period end

Revenue$78.5B +16.9% y/y

Q4 2024Q3 2026

Inventory$44.7B +13.5% y/y

Q4 2024Q3 2026

Accounts receivable$33.1B +12.7% y/y

Q4 2024Q3 2026

Total debt$89.2B +10.9% y/y

Q4 2024Q3 2026

Peers

sample

Sample peer A: $1.14T +5.7% 3M
Sample peer B: $246.7B -5.6% 3M
Sample peer C: $645.9B -3.4% 3M
Sample peer D: $1.05T +8.9% 3M
Sample peer E: $831.1B +5.4% 3M